Gilead finds 'crit­i­cal holes' in the gov­ern­men­t's HIV patent case against it

Gilead’s hop­ing for a swift end to its HIV patent bat­tle with HHS, fil­ing for a sum­ma­ry judg­ment on Thurs­day. If the mo­tion is grant­ed in Gilead’s fa­vor, the case would be dis­missed with­out a tri­al.

The US filed suit against Gilead back in 2019, al­leg­ing that the sale of its HIV drugs Tru­va­da and De­scovy for pre-ex­po­sure pro­phy­lax­is (PrEP) in­fringes on gov­ern­ment-owned patents. While Tru­va­da and De­scovy were ini­tial­ly ap­proved for the treat­ment of HIV back in 2004 and 2016, re­spec­tive­ly, they lat­er picked up ap­provals in the pre­ven­ta­tive set­ting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER